ArticleCureus2025
Coexistence of Nocturia and Frailty and Its Effect on Polypharmacy in Community-Dwelling Older Adults.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEarly interventions for nocturia and frailty are increasingly emphasized to extend healthy life expectancy. These interventions may lead to an increase in the number of drugs administered, potentially resulting in polypharmacy. This study examined the association between nocturia, coexisting frailty, and polypharmacy in community-dwelling older adults.
methodsWe selected 891 older adults without cognitive dysfunction (470 men, 421 women) from a population-based study conducted in 2016 in Kashiwa City, Japan. The association between nocturia, frailty, and polypharmacy was evaluated using sex-stratified logistic regression analysis.
resultsThe prevalence of nocturia, frailty, and their coexistence was 56.4%, 6.2%, and 4.0% in men, and 35.2%, 3.8%, and 2.6% in women, respectively. Polypharmacy was observed in 19.4% of men and 13.1% of women. Compared to the group without nocturia or frailty, the adjusted odds ratio (AOR) for polypharmacy was 2.47 (95% confidence interval (CI): 1.29-4.71) in men and 0.99 (95% CI: 0.50-1.95) in women in the group with either nocturia or frailty. The AORs for the group with both nocturia and frailty were 5.33 (95% CI: 1.56-18.17) in men and 1.20 (95% CI: 0.23-6.17) in women.
conclusionPolypharmacy is more likely in older men when nocturia and frailty coexist. It is important to ensure that the treatment of nocturia and frailty does not result in a significant increase in the number of medications prescribed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.